BRIEF published on 08/08/2024 at 17:50, 3 months 12 days ago Renault Announces Voting Rights and Share Capital as of July 31, 2024 Share Capital Voting Rights AMF Regulation Renault French Stock Market
PRESS RELEASE published on 08/08/2024 at 17:45, 3 months 12 days ago Information relating to the total number of voting rights and share capital - July 31, 2024 Renault S.A. discloses total voting rights and shares as per French regulations. Theoretical voting rights: 401,136,842. Exercisable voting rights: 394,319,094 French Regulations Exercisable Voting Rights Total Voting Rights Renault S.A. Theoretical Voting Rights
PRESS RELEASE published on 07/25/2024 at 07:45, 3 months 27 days ago Renault Group - First half 2024 financial report
BRIEF published on 07/25/2024 at 07:42, 3 months 27 days ago Renault Releases 2024 H1 Financial Report Financial Report Finance Renault 2024 H1 Markets Authority
PRESS RELEASE published on 07/25/2024 at 07:37, 3 months 27 days ago Communication about the availability of 2024 H1 financial report Renault SA releases 2024 H1 Financial Report with French Financial Markets Authority, available on Renault website French Financial Markets Authority Financial Report Regulated Information Renault SA 2024 H1
BRIEF published on 07/17/2024 at 18:35, 4 months 3 days ago Renault Group Appoints Philippe Krief as Chief Technology Officer Chief Technology Officer Automotive Innovation Renault Group Philippe Krief Alpine
PRESS RELEASE published on 07/17/2024 at 18:30, 4 months 3 days ago Renault Group: Philippe Krief appointed Chief Technology Officer of Renault Group Renault Group appoints Philippe Krief as Chief Technology Officer, aiming to drive innovation and lead engineering changes to stay ahead in the automotive industry Innovation Chief Technology Officer Automotive Industry Renault Group Philippe Krief
BRIEF published on 06/21/2024 at 17:50, 4 months 29 days ago Renault Group: Information relating to voting and capital rights as of May 31, 2024 Share Capital Voting Rights Financial Markets Authority Renault
PRESS RELEASE published on 06/21/2024 at 17:45, 4 months 29 days ago Renault Group : Information relating to the total number of voting rights and share capital - May 31, 2024 Renault S.A. discloses the total number of voting rights and shares as per French regulations. Theoretical voting rights: 400,578,405. Exercisable voting rights: 396,085,883 Voting Rights Shares French Regulations Renault S.A. Exercisable
Published on 11/21/2024 at 12:00, 44 minutes ago Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 44 minutes ago Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 14 minutes ago FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 41 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 44 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 12:35, 9 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 29 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 11:30, 1 hour 14 minutes ago APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 06:58, 5 hours 46 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 17 hours 24 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 18 hours 59 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 18 hours 59 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 4 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
